Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Recent trends in the management of relapsing/refractory diffuse large B-cell lymphoma: A systematic review of the literature

View Full Paper
Ask AI
Bookmark
Share

Authors

TDTanja Dudenbostel

Discussion

Loading...

Member takes

Overview

Systematic review reveals CAR-T cell therapy improves outcomes in relapsing/refractory DLBCL, indicating better management strategies.

Key Points

  • CAR-T cell therapy offers superior outcomes compared to conventional treatment in relapsing/refractory DLBCL.
  • A review of 9 studies highlights the efficacy of various CAR-T therapies and their impact on survival rates.
  • Therapeutic modalities such as CAR-T cell therapy show significant improvements in overall and progression-free survival.
  • Cytokine release syndrome was noted more frequently in outpatient settings, suggesting a need for further evaluation.

Cite This Study

Tanja Dudenbostel (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8fdhttps://doi.org/10.1182/blood-2025-7244
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  2. 2Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  3. 3Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  4. 4Feasibility, outcomes and challenges of CAR-T cell therapy as advanced or earlier line of treatment for B-cell non-Hodgkin lymphomas: A multicenter national study2025
  5. 5CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence2025